LM-061 / Sino Biopharm - LARVOL DELTA

Study of LM-061 in Subjects in Advanced Tumors (clinicaltrials.gov) - P1 | N=18 | Terminated | Sponsor: LaNova Medicines Limited | N=37 ➔ 18 | Recruiting ➔ Terminated; Failure to achieve expected outcomes

Enrollment change • Metastases • Trial termination • Oncology

A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours (clinicaltrials.gov) - P1/2 | N=18 | Terminated | Sponsor: LaNova Medicines Limited | N=87 ➔ 18 | Trial completion date: Aug 2024 ➔ Jul 2023 | Recruiting ➔ Terminated | Trial primary completion date: Jul 2023 ➔ Feb 2023; Not meeting expected endpoints

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • MET

A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours (clinicaltrials.gov) - P1/2; N=87; Recruiting; Sponsor: LaNova Medicines Limited; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • EGFR • MET

Study of LM-061 in Subjects in Advanced Tumors (clinicaltrials.gov) - P1; N=37; Recruiting; Sponsor: LaNova Medicines Limited; Initiation date: Dec 2020 ➔ May 2021

Clinical • Trial initiation date • Oncology

Study of LM-061 in Subjects in Advanced Tumors (clinicaltrials.gov) - P1; N=37; Recruiting; Sponsor: LaNova Medicines Limited; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology

A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours (clinicaltrials.gov) - P1/2; N=87; Not yet recruiting; Sponsor: LaNova Medicines Limited

Clinical • New P1/2 trial • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • EGFR • MET